

Fycompa® (perampanel) - First-time generic

- On May 29, 2025, <u>Teva launched</u> an <u>AB-rated</u> generic version of Catalyst's <u>Fycompa</u> (perampanel) tablets.
 - Fycompa is a Schedule III controlled substance.
- Fycompa is approved:
 - For the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older
 - As adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older.
- Fycompa is also available as a brand oral suspension that carries the same indications as Fycompa tablets.
- Fycompa carries a boxed warning for serious psychiatric and behavioral reactions.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.